Toll Like Receptor 3 (CD283 or TLR3) - Drugs in Development, 2021

Published	Pages	Publisher	Report code
Mar 2021	91	Global Markets Direct	ASDR-577315

Published: Mar 2021 - Pages : 91 - Publisher : Global Markets Direct - Report code : ASDR-577315

13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd

Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

This report can be of interest as well:

Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and K...

Published: March, 2022 | Report code: ASDR-599149

Mark your calendar:

Oligonucleotide Therapeutics and Delivery Conference 2024

09 September - 10 September, 2024
London, United Kingdom